Zytoprotec GmbH


  • RDM* biotech/pharma
  • Founded in: 2007
  • Staff: 4
  • Techniques: Cell and tissue culture, Gene and RNA vectors
  • Indications:
    Diseases of the genitourinary system
  • Topic: Human health
  • Cluster Membership: LISAvienna
  • Profile: Zytoprotec is a biotech company that specialises in “cell protection / cell repair” and was founded in February 2007. The company is currently focussing on cytoprotection with the first innovative product for renal therapies: PD-Protec (Phase III ready). The lives of millions of people / patients worldwide can be saved or improved in the long run by these patent-protected research results. Additional products and research areas in the field of cytoprotection are already being planned.
  • R&D: most advanced product(phase III ready) focus on the treatment of patients suffering from kidney failure. For these patients, peritoneal dialysis (PD) is an established treatment option. PD improves quality of life and reduces costs incurred to the health care system in comparison to hemodialysis (HD). Zytoprotec’s clinical studies incl. Phase II Trial have demonstrated that the cytoprotective effects of PD-protec™ promise to protect the peritoneum from damages caused by commercial dialysis.